Table 5 Incremental cost-effectiveness ratio (ICER) by regimen and sensitivity analysis
Regimen | Effectiveness | Total direct cost per patient | ICER | Cost per pathological complete response | No. of patients who needed to be treated to have a pathological complete response | Additional cost for pathological complete response |
|---|---|---|---|---|---|---|
AC-DH | 33% | 40,393 € | 121,180 € | 3.0 | ||
AC-DHP | 45% | 56,375 € | 1370 € | 125,277 € | 2.2 | 4097 € |
Sensitivity analysis | ||||||
Scenario 1. Clinical staging II and negative HR | ||||||
AC-DH | 85% | 40,393 € | 47,640 € | 1.2 | ||
AC-DHP | 90% | 56,375 € | 2955 € | 62,502 € | 1.1 | 14,862 € |
Scenario 2. Clinical staging II and positive HR | ||||||
AC-DH | 54% | 40,393 € | 74,493 € | 1.8 | ||
AC-DHP | 66% | 56,375 € | 1338 € | 85,205 € | 1.5 | 10,711 € |
Scenario 3. Clinical staging III and negative HR | ||||||
AC-DH | 43% | 40,393 € | 93,682 € | 2.3 | ||
AC-DHP | 56% | 56,375 € | 1282 € | 101,427 € | 1.8 | 7745 € |
Scenario 4. Clinical staging III and positive HR | ||||||
AC-DH | 14% | 40,393 € | 291,147 € | 7.2 | ||
AC-DHP | 21% | 56,375 € | 2241 € | 268,371 € | 4.8 | −22,775 € |